

***Plasmodium falciparum*, Strain FCR-1/FVO**

Catalog No. MRA-909

Product Description: *Plasmodium falciparum* (*P. falciparum*), strain FCR-1/FVO started at the Rockefeller University in 1976, by continuous culture of the Vietnam-Oak Knoll (FVO) strain. The parent *P. falciparum* FVO strain, which is chloroquine-resistant, was originally isolated from a patient who returned from Vietnam and was hospitalized at the Oak Knoll Naval Hospital, Oakland, California, USA. MRA-909 was derived from ATCC® 30930™, which was deposited at ATCC® by W. Trager. *P. falciparum*, strain FCR-1/FVO was deposited as chloroquine-resistant.

Lot¹: 70011949

Manufacturing Date: 06FEB2018

TEST	SPECIFICATIONS	RESULTS
Identification by Giemsa Stain Microscopy^{2,3}	Blood-stage parasites present	Blood-stage parasites present
Antimalarial Susceptibility Profile (<i>in vitro</i>)² Half-maximal Inhibitory Concentration (IC ₅₀) by SYBR green I® drug sensitivity assay ⁴ Chloroquine Artemisinin Quinine Cycloguanil Pyrimethamine Sulfadoxine	Report results Report results Report results Report results Report results Report results	55.7 ± 2.6 nM 11.6 ± 0.5 nM 289.5 ± 26.7 nM 1013.0 ± 93.4 nM 30.6 ± 3.5 nM 23750 ± 5517 nM
Genotypic Analysis² Sequencing of Merozoite Surface Protein 2 (MSP2) gene (~ 680 base pairs)	Consistent with <i>P. falciparum</i>	Consistent with <i>P. falciparum</i> (Figure 1)
Functional Activity by PCR Amplification² MSP2 PCR amplicon analysis ⁵	~ 600 to 900 base pair amplicon	~ 800 base pair amplicon
Level of Parasitemia Pre-freeze ^{6,7} Ring-stage parasitemia Total parasitemia Post-freeze ^{2,8} Ring-stage parasitemia Total parasitemia	Report results ≥ 2% Report results ≥ 1%	2.15% 4.65% 2.06% 2.94%
Viability^{2,9}	Growth in infected red blood cells	Growth in infected red blood cells
Sterility (21-day incubation)² Harpo's HTYE broth ¹⁰ , 37°C and 26°C, aerobic Tryptic Soy broth, 37°C and 26°C, aerobic Sabouraud Dextrose broth, 37°C and 26°C, aerobic DMEM with 10% FBS, 37°C, aerobic Sheep Blood agar, 37°C, aerobic Sheep Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic	No growth No growth No growth No growth No growth No growth No growth	No growth No growth No growth No growth No growth No growth No growth
Mycoplasma Contamination² DNA Detection by PCR	None detected	None detected

¹MRA-909 was produced by cultivation of BEI Resources MR-MRA-909 lot 58218068 in fresh human erythrocytes suspended in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 µg/mL hypoxanthine and 2.5 µg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N₂,

- 5% CO₂, 5% O₂) and monitored for parasitemia daily for 8 days. Every 2 to 3 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture as needed and monitored for hematocrit.
- ²Testing completed on viald post-freeze material.
- ³Blood-stage malaria parasites (rings, trophozoites, schizonts +/- gametocytes) were examined by microscopic Giemsa-stained blood smears of an *in vitro* human blood culture over 3 days.
- ⁴A SYBR Green I[®] anti-malarial drug sensitivity assay in 96-well plates was used to determine IC₅₀ values of an active (> 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I[®]-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In *Methods in Malaria Research Sixth Edition*. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: <https://www.beiresources.org/Publications/MethodsInMalariaResearch.aspx>].
- ⁵Primer sequences and conditions for PCR are available upon request.
- ⁶Testing completed on bulk material prior to vialing and freezing.
- ⁷Parasitemia was determined after 8 days post infection by microscopic counts of Giemsa-stained blood smears.
- ⁸Post-freeze parasitemia was determined after 3 days post infection by microscopic counts of Giemsa-stained blood smears.
- ⁹Viability was confirmed by examination of infected erythrocytes for parasitemia at 3 days post infection.
- ¹⁰Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

Figure 1: MRA-909 MSP2 Sequence

```
TGAAAGTAAA TATAGCAACA CATTCAATAA CAATGCTTAT AATATGAGTA TAAGGAGAAG TATGACAGAA AGTAATCCTC
CTACTGGTGC TAGTGGTAGT GCTGGTGGTA GTGCTGGTGG TAGTGCTGGT GGTAGTGCTG GTGGTAGTGC TGGTGGTAGT
GCTGGTGGTA GTGCTGGTGG TAGTGCTGGT GGTAGTGCTG GTGGTAGTGC TGGTGGTAGT GCTGGTGGTA GTGCTGGTGG
TAGTGCTGGT TCTGGTGATG GTAATGGTGC TAATCCTGGT GCAGATGCTG AGAGAAGTCC AAGTACTCCC GCTACTACCA
CAACTACCAC AACTACTAAT GATGCAGAAG CATCTACCAG TACCTCTTCA GAAAATCCAA ATCATAATAA TGCCGAAACA
AATCAAGCAA ATAAAGAAAC TCAAAATAAC TCAAATGTTC AACAAGACTC TCAAATAAAA TCAAATGTTC CACCCACTCA
AGATGCAGAC ACTAAAAGTC CTACTGCACA ACCTGAACAA GCTGAAAATT CTGCTMCAAC AGCCGAACAA ACTGAATCCC
CCGAATTMCA ATCTGCACCA GAGAATAAAG GTACAGGACA ACATGGACAT ATGCATGGTT CTAGAAATAA TCATCCACAA
AATACTTCTG ATAGTCAAAA AGAATGTACC GATGGTAACA AAGA
```

/Heather Couch/
Heather Couch

Program Manager or designee, ATCC Federal Solutions

02 OCT 2018

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection.
You are authorized to use this product for research use only. It is not intended for human use.

